Recent Analysts’ Ratings Updates for Icon (ICLR)

Icon (NASDAQ: ICLR) recently received a number of ratings updates from brokerages and research firms:

• 6/1/2026 – Icon was given a new $164.00 price target by DA Davidson.
• 6/1/2026 – Icon had its price target raised by TD Cowen from $120.00 to $164.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Icon had its “outperform” rating reaffirmed by Bank of America Corporation.
• 5/29/2026 – Icon was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/29/2026 – Icon had its price target raised by Truist Financial Corporation from $139.00 to $159.00. They now have a “hold” rating on the stock.
• 5/29/2026 – Icon had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $165.00 price target on the stock.
• 5/29/2026 – Icon had its price target raised by Royal Bank Of Canada from $123.00 to $126.00. They now have a “sector perform” rating on the stock.
• 5/29/2026 – Icon had its price target raised by Citigroup Inc. from $120.00 to $140.00. They now have a “neutral” rating on the stock.
• 5/29/2026 – Icon had its price target raised by JPMorgan Chase & Co. from $120.00 to $130.00. They now have a “neutral” rating on the stock.
• 5/29/2026 – Icon had its price target raised by Barclays PLC from $120.00 to $150.00. They now have an “equal weight” rating on the stock.
• 5/29/2026 – Icon had its price target raised by BMO Capital Markets from $130.00 to $160.00. They now have an “outperform” rating on the stock.
• 5/28/2026 – Icon was downgraded by Piper Sandler to “neutral”.
• 5/28/2026 – Icon was given a new $145.00 price target by Leerink Partners.
• 5/27/2026 – Icon had its price target raised by Bank of America Corporation to $105.00. They now have an “underperform” rating on the stock.
• 5/18/2026 – Icon had its price target lowered by JPMorgan Chase & Co. from $175.00 to $120.00. They now have a “neutral” rating on the stock.
• 5/18/2026 – Icon is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $123.00 price target on the stock.
• 5/4/2026 – Icon was given a new $125.00 price target by Leerink Partners.

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.